ASH 2025 | Ponatinib plus blinatumomab versus imatinib and chemotherapy in Ph+ ALL: the GIMEMA ALL2820 trial
Sabina Chiaretti
• 5 Dec 2025
Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares the first results of the Phase III GIMEMA ALL2820 trial (NCT04722848) comparing ponatinib plus blinatumomab to imatinib and chemotherapy for newly diagnosed adult Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). Dr Chiaretti reports findings suggesting that a chemotherapy-free targeted approach based on ponatinib, possibly plus immunotherapy, should be the way to treat patients with newly diagnosed Ph+ ALL. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
